Literature DB >> 19898238

Accelerated arteriosclerosis: a form of transplant arteriopathy.

Gary S Hill1, Dominique Nochy, Alexandre Loupy.   

Abstract

PURPOSE OF REVIEW: Terminology for posttransplant renal arterial lesions is confusing, with multiple terms being applied, the more common among them being the comprehensive terms, transplant arteriosclerosis and transplant atherosclerosis; endarteritis, for intimal lesions with an inflammatory component; and finally for advanced lesions with or without intimal inflammation, transplant arteriopathy. However, these latter lesions may present the appearance of banal arteriosclerosis, albeit more advanced expected on the basis of donor age. This review explores the distinctions to be drawn among these various descriptive terms. RECENT
FINDINGS: Cell-mediated arterial lesions due to T-cell cell-endothelial interactions and antibody-mediated lesions, due to antiendothelial cell antibodies, show many common features: myofibroblasts, some of recipient origin, laying down extracellular matrix. However, they differ in that cell-mediated intimal lesions initially have a prominent leukocytic component, usually absent in antibody-mediated lesions. The antibodies most frequently implicated are antihuman leukocyte antigen class I and class 2 antibodies. With the exception of a sometimes more cellular intima and initial absence of dense collagen and elastic fibers, these latter lesions resemble those of arteriosclerosis of aging.
SUMMARY: Many instances of lesions designated as transplant arteriopathy are morphologically similar or identical to typical renal arteriosclerosis and could equally be regarded as accelerated arteriosclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19898238     DOI: 10.1097/MOT.0b013e3283342684

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  6 in total

Review 1.  The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.

Authors:  Alexandre Loupy; Gary S Hill; Stanley C Jordan
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

2.  Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.

Authors:  Gary S Hill; Dominique Nochy; Patrick Bruneval; J P Duong van Huyen; Denis Glotz; Caroline Suberbielle; Julien Zuber; Dany Anglicheau; Jean-Philippe Empana; Christophe Legendre; Alexandre Loupy
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

3.  Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports.

Authors:  Eric Siskind; Madhu Bhaskaran; Fouad Boctor; Kavin Shah; Ernesto Molmenti
Journal:  Int J Angiol       Date:  2012-06

Review 4.  Current pathological perspectives on chronic rejection in renal allografts.

Authors:  Shigeo Hara
Journal:  Clin Exp Nephrol       Date:  2016-11-16       Impact factor: 2.801

5.  Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates.

Authors:  Carrie A Schinstock; Manish Gandhi; Wisit Cheungpasitporn; Donald Mitema; Mikel Prieto; Patrick Dean; Lynn Cornell; Fernando Cosio; Mark Stegall
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

Review 6.  Vascular endothelium as a target of immune response in renal transplant rejection.

Authors:  Giovanni Piotti; Alessandra Palmisano; Umberto Maggiore; Carlo Buzio
Journal:  Front Immunol       Date:  2014-10-21       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.